Drug profile

The FDA adverse-event record for Canine Bb/Pi3/Adeno 2 Lv/Lb

284 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Bb/Pi3/Adeno 2 Lv/Lb. See the species affected, top reactions, and outcomes below.

284
adverse-event reports
14.4%
death-coded share
Dog
most-reported species
75
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
284
Total Reports
41
Deaths Reported
14.4%
Death Rate

Active Ingredients

Canine Bb/Pi3/Adeno 2 Lv/Lb

Administration Routes

NasalUnknownSubcutaneous

Species Affected

Dog 284

Most Affected Breeds

Crossbred Canine/dog 64
Terrier (unspecified) 14
Shih Tzu 13
Retriever - Labrador 13
Retriever - Golden 12
Boxer (German Boxer) 11
Shepherd Dog - German 10
Schnauzer - Miniature 10
Chihuahua 9
Pointing Dog - German Short-haired 9

Most Reported Reactions

Vomiting 75
Lethargy (see also Central nervous system depression in 'Neurological') 56
Emesis (multiple) 52
Diarrhoea 38
Cough 27
Anorexia 27
Death by euthanasia 23
Not eating 22
Other abnormal test result NOS 18
Seizure NOS 18
Death 17
Fever 17

Outcome Breakdown

Recovered/Normal
121 (42.6%)
Ongoing
85 (29.9%)
Outcome Unknown
33 (11.6%)
Euthanized
24 (8.5%)
Died
17 (6.0%)
Recovered with Sequela
4 (1.4%)

Canine Bb/Pi3/Adeno 2 Lv/Lb Adverse Event Insights

284 reports name Canine Bb/Pi3/Adeno 2 Lv/Lb; 41 recorded a death outcome (14.4% of reported events, not a population-level mortality rate). Active ingredient: Canine Bb/Pi3/Adeno 2 Lv/Lb. Administration routes: Nasal, Unknown, Subcutaneous.

By species: Dog (284 reports). By breed: Crossbred Canine/dog (64), Terrier (unspecified) (14), Shih Tzu (13).

Leading clinical signs: Vomiting (75), Lethargy (see also Central nervous system depression in 'Neurological') (56), Emesis (multiple) (52), Diarrhoea (38). Outcome, 284 coded reports: Recovered/Normal leads at 42.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.